<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Supplementary Material</title>
    <style>
        body {
            font-family: 'Helvetica Neue', Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f9f9f9;
            color: #333;
        }
        header {
            background-color: #720026;
            color: #fff;
            padding: 20px;
            text-align: center;
        }
        h1 {
            margin: 0;
            font-size: 24px;
        }
        .container {
            padding: 20px;
        }
        h2 {
            color: #720026;
            border-bottom: 2px solid #ce4257;
            padding-bottom: 5px;
            font-size: 20px;
        }
        p {
            font-size: 14px;
            line-height: 1.6;
        }
        .pdf-section {
            margin-bottom: 40px;
            text-align: center;
        }
        .download-button {
            display: inline-block;
            padding: 10px 20px;
            margin-bottom: 10px;
            background-color: #ce4257;
            color: #fff;
            text-decoration: none;
            border-radius: 5px;
            transition: background-color 0.3s ease;
        }
        .download-button:hover {
            background-color: #a33d4a;
        }
        .pdf-embed {
            width: 100%;
            height: 600px;
            border: none;
            margin-bottom: 20px;
        }
        table {
            width: 100%;
            border-collapse: collapse;
            margin-bottom: 40px;
            background-color: #fff;
            overflow-x: auto;
        }
        th, td {
            border: 1px solid #ddd;
            padding: 8px 12px;
            text-align: left;
            vertical-align: top;
            font-size: 14px;
        }
        th {
            background-color: #ce4257;
            color: #fff;
        }
        tr:nth-child(even) {
            background-color: #f2f2f2;
        }
        .references {
            list-style-type: decimal;
            padding-left: 20px;
            font-size: 14px;
        }
        .reference-item {
            margin-bottom: 10px;
        }
        footer {
            background-color: #720026;
            color: #fff;
            text-align: center;
            padding: 10px;
            position: relative;
            font-size: 14px;
        }
        /* Responsive Tables */
        @media (max-width: 768px) {
            h1 {
                font-size: 20px;
            }
            h2 {
                font-size: 18px;
            }
            p, th, td, .references, .reference-item, footer {
                font-size: 12px;
            }
            .pdf-embed {
                height: 400px;
            }
            .download-button {
                padding: 8px 16px;
                font-size: 14px;
            }
            table, thead, tbody, th, td, tr {
                display: block;
            }
            thead tr {
                display: none;
            }
            tr {
                margin-bottom: 10px;
            }
            td {
                border: none;
                position: relative;
                padding-left: 50%;
                text-align: right;
            }
            td::before {
                position: absolute;
                top: 8px;
                left: 12px;
                width: 45%;
                padding-right: 10px;
                white-space: nowrap;
                font-weight: bold;
                text-align: left;
            }
            /* Add labels to table cells */
            td:nth-of-type(1)::before { content: "Variable"; }
            td:nth-of-type(2)::before { content: "1"; }
            td:nth-of-type(3)::before { content: "2"; }
            td:nth-of-type(4)::before { content: "3"; }
            td:nth-of-type(5)::before { content: "4"; }
            td:nth-of-type(6)::before { content: "5"; }
            td:nth-of-type(7)::before { content: "6"; }
            td:nth-of-type(8)::before { content: "7"; }
        }
    </style>
</head>
<body>

    <header>
        <h1>Supplement to Sex-Based Disparities in Cost-Related Medication Nonadherence in Older Adult Patients with Type 2 Diabetes from the All of Us Database</h1>
    </header>

    <div class="container">
        <!-- Embed PDF Section -->
        <div class="pdf-section">
            <a href="Poster PDF.pdf" download class="download-button">Download PDF</a>
            <iframe src="Poster PDF.pdf" class="pdf-embed">
                This browser does not support PDFs. Please download the PDF to view it: <a href="Poster PDF.pdf">Download PDF</a>.
            </iframe>
        </div>

        <!-- Supplemental Tables -->
        
        <!-- Supplemental Table 1 -->
        <h2>Supplemental Table 1: ICD-9 and ICD-10 Codes Utilized For Cohort Identification</h2>
        <p>
            ICD-10 and ICD-9 codes utilized to collect cohorts from the All of Us researcher workbench are detailed below. 
            From left to right, the columns include the prospective cohort, followed by utilized ICD-10 codes, and lastly followed by utilized ICD-9 codes.
        </p>
        <table>
            <thead>
                <tr>
                    <th>Prospective Cohort</th>
                    <th>ICD-10</th>
                    <th>ICD-9</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Type 2 Diabetes</td>
                    <td>E11</td>
                    <td>250.x0, 250.x2</td>
                </tr>
                <!-- Add more rows as needed -->
            </tbody>
        </table>

        <!-- Supplemental Table 2 -->
        <h2>Supplemental Table 2: Medications Considered in All of Us Researcher Workbench Queries for Type 2 Diabetes</h2>
        <p>
            The column on the left represents the medication class, while the column on the right represents the generic names considered within each medication class.
        </p>
        <table>
            <thead>
                <tr>
                    <th>Medication Class</th>
                    <th>Medications Related to Type 2 Diabetes Treatments</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Biguanide</td>
                    <td>Metformin</td>
                </tr>
                <tr>
                    <td>DPP-4 Inhibitors</td>
                    <td>Alogliptin, Linagliptin, Saxagliptin, Sitagliptin</td>
                </tr>
                <tr>
                    <td>GLP-1 and Dual GLP-1/GIP Receptor Antagonists</td>
                    <td>Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide</td>
                </tr>
                <tr>
                    <td>SGLT 2 Inhibitors</td>
                    <td>Canagliflozin, Dapagliflozin, Empagliflozin</td>
                </tr>
                <tr>
                    <td>Sulfonylureas</td>
                    <td>Glimepiride, Glipizide, Glyburide</td>
                </tr>
                <tr>
                    <td>Thiazolidinediones</td>
                    <td>Rosiglitazone, Pioglitazone</td>
                </tr>
                <tr>
                    <td>Alpha-glucosidase Inhibitors</td>
                    <td>Acarbose, Miglitol</td>
                </tr>
                <tr>
                    <td>Bile Acid Sequestrants</td>
                    <td>Colesevelam</td>
                </tr>
                <tr>
                    <td>Dopamine-2 Agonists</td>
                    <td>Bromocriptine</td>
                </tr>
                <tr>
                    <td>Meglitinides</td>
                    <td>Nateglinide, Repaglinide</td>
                </tr>
                <tr>
                    <td>Insulins and analogues</td>
                    <td>Insulins and analogues</td>
                </tr>
                <!-- Add more rows as needed -->
            </tbody>
        </table>

        <!-- Supplemental Table 3 -->
        <h2>Supplemental Table 3: Data Sources within All of Us Researcher Workbench</h2>
        <p>
            The first column indicates the data source within All of Us researcher workbench, the second indicates how the data was accessed, and the third lists information taken from each source to conduct our study.
        </p>
        <table>
            <thead>
                <tr>
                    <th>Source</th>
                    <th>Access</th>
                    <th>Data Utilized</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Healthcare Access & Utilization Surveys</td>
                    <td>Concept Sets &gt;<br>Healthcare Access & Utilization<br>Cost Related Medication Adherence Surveys</td>
                    <td>Cost Related Medication Adherence Surveys</td>
                </tr>
                <tr>
                    <td>Lifestyle Surveys</td>
                    <td>Concept Sets &gt;<br>Lifestyle Surveys</td>
                    <td>Smoking History</td>
                </tr>
                <tr>
                    <td>The Basics Surveys</td>
                    <td>Concept Sets &gt;<br>The Basics Surveys</td>
                    <td>Biological Sex, Race, Ethnicity, Income, Education Status, Age</td>
                </tr>
                <tr>
                    <td>Electronic Health Records (EHR)</td>
                    <td>Concept Sets &gt;<br>Drug Exposures</td>
                    <td>Past medication use</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Concept Sets &gt;<br>Conditions (ICD-9/ICD-10 codes)</td>
                    <td>Type 2 Diabetes Diagnosis, Comorbidity Diagnosis</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Concept Sets &gt;<br>Labs and Measurements/Observations/Physical Measurements</td>
                    <td>Body Mass Index (BMI)</td>
                </tr>
            </tbody>
        </table>

        <!-- Supplemental Table 4 -->
        <h2>Supplemental Table 4: Odds Ratios in Adjusted Logistic Regression Models for Cost-Related Medication Adherence Questions within Type 2 Diabetes Cohort</h2>
        <p>
            From left to right each column represents reported odds ratios relevant to each CRMA survey question (Question 1 through Q7 detailed in Table 1). Each row represents a variable included in the adjusted models, with reference categories for certain categorical variables indicated (ref= “ ”) in the first column with the variable name.
        </p>
        <table id="table4" class="table table-bordered table-hover table-condensed">
            <thead>
                <tr>
                    <th>Variable</th>
                    <th>1</th>
                    <th>2</th>
                    <th>3</th>
                    <th>4</th>
                    <th>5</th>
                    <th>6</th>
                    <th>7</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Sex at Birth (ref = Male)</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
                <tr>
                    <td>Female Sex at Birth</td>
                    <td>1.28 (1.07-1.53)**</td>
                    <td>1.46 (1.16-1.84)**</td>
                    <td>1.26 (1.01-1.58)*</td>
                    <td>1.25 (1.03-1.51)*</td>
                    <td>1.04 (0.91-1.19)</td>
                    <td>0.64 (0.46-0.87)**</td>
                    <td>1.06 (0.79-1.43)</td>
                </tr>
                <tr>
                    <td>Age</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
                <tr>
                    <td>Age (each additional year of age)</td>
                    <td>0.94 (0.92-0.95)***</td>
                    <td>0.93 (0.91-0.96)***</td>
                    <td>0.94 (0.92-0.96)***</td>
                    <td>0.93 (0.92-0.95)***</td>
                    <td>0.97 (0.96-0.98)***</td>
                    <td>0.99 (0.96-1.02)</td>
                    <td>0.93 (0.9-0.96)***</td>
                </tr>
                <tr>
                    <td>Race/Ethnicity (Ref = Non-Hispanic White)</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
                <tr>
                    <td>Hispanic/Latino</td>
                    <td>1.07 (0.8-1.44)</td>
                    <td>0.75 (0.5-1.12)</td>
                    <td>0.8 (0.54-1.19)</td>
                    <td>0.68 (0.48-0.97)*</td>
                    <td>0.56 (0.42-0.74)***</td>
                    <td>1.39 (0.8-2.43)</td>
                    <td>0.98 (0.58-1.65)</td>
                </tr>
                <tr>
                    <td>Non-Hispanic Black</td>
                    <td>1.13 (0.9-1.42)</td>
                    <td>0.86 (0.64-1.14)</td>
                    <td>0.83 (0.62-1.1)</td>
                    <td>0.87 (0.68-1.12)</td>
                    <td>0.63 (0.51-0.77)***</td>
                    <td>0.38 (0.19-0.76)**</td>
                    <td>1.0 (0.68-1.47)</td>
                </tr>
                <tr>
                    <td>Other</td>
                    <td>0.98 (0.63-1.54)</td>
                    <td>1.33 (0.8-2.2)</td>
                    <td>1.04 (0.62-1.75)</td>
                    <td>0.88 (0.55-1.4)</td>
                    <td>1.1 (0.81-1.5)</td>
                    <td>1.42 (0.76-2.65)</td>
                    <td>1.48 (0.8-2.74)</td>
                </tr>
                <tr>
                    <td>Income (ref = &lt;25k)</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
                <tr>
                    <td>25,000 - 50,000</td>
                    <td>1.21 (0.95-1.54)</td>
                    <td>1.08 (0.8-1.44)</td>
                    <td>1.18 (0.88-1.57)</td>
                    <td>1.42 (1.09-1.83)**</td>
                    <td>1.63 (1.32-2.0)***</td>
                    <td>3.58 (1.91-6.72)***</td>
                    <td>1.08 (0.72-1.62)</td>
                </tr>
                <tr>
                    <td>50,000 - 100,000</td>
                    <td>0.74 (0.59-0.92)**</td>
                    <td>0.58 (0.43-0.77)***</td>
                    <td>0.62 (0.47-0.83)**</td>
                    <td>0.7 (0.55-0.9)**</td>
                    <td>1.1 (0.91-1.34)</td>
                    <td>2.83 (1.57-5.09)***</td>
                    <td>0.72 (0.49-1.05)</td>
                </tr>
                <tr>
                    <td>100,000 - 150,000</td>
                    <td>0.44 (0.3-0.65)***</td>
                    <td>0.22 (0.12-0.39)***</td>
                    <td>0.28 (0.17-0.46)***</td>
                    <td>0.47 (0.32-0.69)***</td>
                    <td>0.77 (0.59-1.01)</td>
                    <td>2.87 (1.42-5.8)**</td>
                    <td>0.22 (0.1-0.45)***</td>
                </tr>
                <tr>
                    <td>&gt;150,000</td>
                    <td>0.35 (0.21-0.56)***</td>
                    <td>0.2 (0.1-0.41)***</td>
                    <td>0.24 (0.13-0.46)***</td>
                    <td>0.3 (0.18-0.51)***</td>
                    <td>0.62 (0.45-0.84)**</td>
                    <td>2.51 (1.16-5.43)*</td>
                    <td>0.12 (0.04-0.36)***</td>
                </tr>
                <tr>
                    <td>Education (Ref = &lt;high school or equiv)</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
                <tr>
                    <td>High School or GED</td>
                    <td>0.83 (0.57-1.21)</td>
                    <td>1.61 (0.95-2.74)</td>
                    <td>1.63 (0.95-2.79)</td>
                    <td>1.18 (0.74-1.86)</td>
                    <td>1.21 (0.83-1.76)</td>
                    <td>0.46 (0.2-1.04)</td>
                    <td>1.41 (0.65-3.08)</td>
                </tr>
                <tr>
                    <td>Some College/Vocational</td>
                    <td>1.16 (0.82-1.65)</td>
                    <td>1.72 (1.03-2.87)*</td>
                    <td>2.03 (1.22-3.4)**</td>
                    <td>1.43 (0.93-2.22)</td>
                    <td>1.61 (1.13-2.3)**</td>
                    <td>0.68 (0.33-1.4)</td>
                    <td>2.06 (0.99-4.3)</td>
                </tr>
                <tr>
                    <td>College or Advanced Degree</td>
                    <td>1.01 (0.71-1.45)</td>
                    <td>1.7 (1.01-2.85)*</td>
                    <td>1.88 (1.11-3.17)*</td>
                    <td>1.5 (0.96-2.33)</td>
                    <td>1.57 (1.1-2.25)*</td>
                    <td>0.87 (0.43-1.77)</td>
                    <td>2.25 (1.07-4.74)*</td>
                </tr>
                <tr>
                    <td>Insurance (Ref = Employer or Union)</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
                <tr>
                    <td>Employer or Union + Medicare</td>
                    <td>1.0 (0.66-1.52)</td>
                    <td>0.99 (0.58-1.68)</td>
                    <td>0.81 (0.49-1.33)</td>
                    <td>1.1 (0.74-1.64)</td>
                    <td>0.87 (0.66-1.15)</td>
                    <td>1.1 (0.57-2.12)</td>
                    <td>0.87 (0.49-1.55)</td>
                </tr>
                <tr>
                    <td>Medicaid</td>
                    <td>0.99 (0.65-1.5)</td>
                    <td>0.83 (0.48-1.43)</td>
                    <td>0.74 (0.44-1.25)</td>
                    <td>0.49 (0.29-0.83)**</td>
                    <td>0.56 (0.38-0.82)**</td>
                    <td>1.04 (0.43-2.51)</td>
                    <td>0.48 (0.24-0.94)*</td>
                </tr>
                <tr>
                    <td>Medicaid + Medicare</td>
                    <td>1.24 (0.81-1.88)</td>
                    <td>0.95 (0.54-1.66)</td>
                    <td>0.91 (0.54-1.54)</td>
                    <td>1.12 (0.71-1.75)</td>
                    <td>0.6 (0.41-0.89)*</td>
                    <td>1.23 (0.49-3.1)</td>
                    <td>0.6 (0.3-1.21)</td>
                </tr>
                <tr>
                    <td>Medicare</td>
                    <td>1.94 (1.45-2.59)***</td>
                    <td>1.76 (1.22-2.54)**</td>
                    <td>1.5 (1.07-2.09)*</td>
                    <td>1.65 (1.24-2.21)***</td>
                    <td>1.59 (1.3-1.95)***</td>
                    <td>1.85 (1.12-3.06)*</td>
                    <td>0.81 (0.54-1.23)</td>
                </tr>
                <tr>
                    <td>Medicare + Other</td>
                    <td>0.39 (0.18-0.83)*</td>
                    <td>0.23 (0.07-0.76)*</td>
                    <td>0.4 (0.17-0.9)*</td>
                    <td>0.4 (0.19-0.83)*</td>
                    <td>0.33 (0.21-0.51)***</td>
                    <td>0.11 (0.01-0.82)*</td>
                    <td>0.4 (0.15-1.06)</td>
                </tr>
                <tr>
                    <td>Medicare + Purchased</td>
                    <td>1.93 (1.31-2.85)***</td>
                    <td>1.37 (0.82-2.3)</td>
                    <td>1.28 (0.8-2.04)</td>
                    <td>1.42 (0.95-2.12)</td>
                    <td>2.14 (1.65-2.79)***</td>
                    <td>1.55 (0.81-2.97)</td>
                    <td>0.99 (0.55-1.8)</td>
                </tr>
                <tr>
                    <td>Mixed</td>
                    <td>1.1 (0.62-1.96)</td>
                    <td>1.02 (0.49-2.14)</td>
                    <td>0.62 (0.28-1.35)</td>
                    <td>0.99 (0.55-1.79)</td>
                    <td>0.82 (0.55-1.23)</td>
                    <td>1.16 (0.47-2.85)</td>
                    <td>0.75 (0.32-1.77)</td>
                </tr>
                <tr>
                    <td>No Insurance</td>
                    <td>2.47 (1.5-4.07)***</td>
                    <td>3.43 (1.92-6.1)***</td>
                    <td>2.61 (1.48-4.61)***</td>
                    <td>2.73 (1.64-4.56)***</td>
                    <td>1.1 (0.68-1.79)</td>
                    <td>2.29 (0.86-6.09)</td>
                    <td>1.25 (0.57-2.74)</td>
                </tr>
                <tr>
                    <td>Other</td>
                    <td>1.07 (0.64-1.77)</td>
                    <td>0.86 (0.44-1.7)</td>
                    <td>0.63 (0.32-1.24)</td>
                    <td>0.7 (0.39-1.25)</td>
                    <td>0.66 (0.45-0.98)*</td>
                    <td>0.79 (0.29-2.14)</td>
                    <td>0.77 (0.37-1.6)</td>
                </tr>
                <tr>
                    <td>Purchased</td>
                    <td>1.69 (0.99-2.89)</td>
                    <td>1.22 (0.6-2.46)</td>
                    <td>0.78 (0.37-1.65)</td>
                    <td>0.98 (0.53-1.82)</td>
                    <td>1.45 (0.97-2.18)</td>
                    <td>0.55 (0.13-2.4)</td>
                    <td>0.12 (0.02-0.85)*</td>
                </tr>
                <tr>
                    <td>BMI (ref = &gt;30)</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
                <tr>
                    <td>&lt;18.5</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                </tr>
                <tr>
                    <td>18.5 - 25</td>
                    <td>0.75 (0.55-1.03)</td>
                    <td>0.62 (0.4-0.96)*</td>
                    <td>0.72 (0.48-1.07)</td>
                    <td>0.84 (0.6-1.17)</td>
                    <td>0.88 (0.7-1.1)</td>
                    <td>1.34 (0.85-2.11)</td>
                    <td>0.74 (0.43-1.26)</td>
                </tr>
                <tr>
                    <td>25 - 30</td>
                    <td>0.89 (0.73-1.08)</td>
                    <td>0.97 (0.76-1.25)</td>
                    <td>0.95 (0.75-1.22)</td>
                    <td>1.06 (0.86-1.3)</td>
                    <td>1.03 (0.89-1.19)</td>
                    <td>1.14 (0.82-1.59)</td>
                    <td>0.92 (0.66-1.28)</td>
                </tr>
                <tr>
                    <td>Medications</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
                <tr>
                    <td>Biguanide</td>
                    <td>0.95 (0.77-1.17)</td>
                    <td>0.9 (0.7-1.17)</td>
                    <td>0.74 (0.58-0.95)*</td>
                    <td>0.95 (0.77-1.18)</td>
                    <td>0.94 (0.8-1.1)</td>
                    <td>0.79 (0.55-1.13)</td>
                    <td>0.83 (0.6-1.17)</td>
                </tr>
                <tr>
                    <td>DPP-4 Inhibitors</td>
                    <td>1.18 (0.96-1.45)</td>
                    <td>1.09 (0.84-1.42)</td>
                    <td>1.13 (0.88-1.46)</td>
                    <td>1.28 (1.03-1.58)*</td>
                    <td>1.11 (0.95-1.3)</td>
                    <td>0.99 (0.67-1.45)</td>
                    <td>1.04 (0.72-1.49)</td>
                </tr>
                <tr>
                    <td>GLP-1 and Dual GLP-1/GIP Receptor Antagonists</td>
                    <td>1.08 (0.89-1.31)</td>
                    <td>1.1 (0.86-1.41)</td>
                    <td>1.3 (1.03-1.64)*</td>
                    <td>1.08 (0.88-1.33)</td>
                    <td>1.2 (1.04-1.4)*</td>
                    <td>0.83 (0.56-1.21)</td>
                    <td>1.4 (1.02-1.93)*</td>
                </tr>
                <tr>
                    <td>SGLT 2 Inhibitors</td>
                    <td>0.99 (0.8-1.22)</td>
                    <td>1.18 (0.9-1.54)</td>
                    <td>1.16 (0.9-1.49)</td>
                    <td>0.91 (0.73-1.15)</td>
                    <td>0.88 (0.75-1.04)</td>
                    <td>1.13 (0.77-1.67)</td>
                    <td>0.96 (0.67-1.39)</td>
                </tr>
                <tr>
                    <td>Sulfonylureas</td>
                    <td>1.06 (0.89-1.27)</td>
                    <td>1.13 (0.9-1.42)</td>
                    <td>1.03 (0.82-1.29)</td>
                    <td>1.04 (0.86-1.26)</td>
                    <td>1.12 (0.98-1.29)</td>
                    <td>0.87 (0.62-1.22)</td>
                    <td>0.68 (0.49-0.94)*</td>
                </tr>
                <tr>
                    <td>Thiazolidinediones</td>
                    <td>0.93 (0.73-1.18)</td>
                    <td>0.76 (0.55-1.05)</td>
                    <td>0.92 (0.69-1.24)</td>
                    <td>0.91 (0.71-1.18)</td>
                    <td>0.88 (0.73-1.06)</td>
                    <td>0.72 (0.45-1.16)</td>
                    <td>0.75 (0.48-1.19)</td>
                </tr>
                <tr>
                    <td>Alpha-glucosidase Inhibitors</td>
                    <td>1.1 (0.56-2.14)</td>
                    <td>0.7 (0.25-1.96)</td>
                    <td>0.97 (0.41-2.31)</td>
                    <td>0.71 (0.3-1.67)</td>
                    <td>1.3 (0.79-2.16)</td>
                    <td>0.39 (0.05-2.9)</td>
                    <td>0.7 (0.17-2.96)</td>
                </tr>
                <tr>
                    <td>Bile Acid Sequestrants</td>
                    <td>1.28 (0.72-2.27)</td>
                    <td>1.24 (0.6-2.53)</td>
                    <td>1.28 (0.65-2.54)</td>
                    <td>1.14 (0.62-2.09)</td>
                    <td>1.04 (0.66-1.64)</td>
                    <td>1.25 (0.44-3.51)</td>
                    <td>0.75 (0.23-2.42)</td>
                </tr>
                <tr>
                    <td>Dopamine-2 Agonists</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                </tr>
                <tr>
                    <td>Meglitinides</td>
                    <td>1.46 (0.97-2.21)</td>
                    <td>1.73 (1.06-2.83)*</td>
                    <td>1.44 (0.88-2.37)</td>
                    <td>1.65 (1.09-2.5)*</td>
                    <td>1.68 (1.22-2.32)**</td>
                    <td>2.15 (1.14-4.08)*</td>
                    <td>1.16 (0.55-2.48)</td>
                </tr>
                <tr>
                    <td>Insulins and Analogues</td>
                    <td>1.36 (1.13-1.64)**</td>
                    <td>1.35 (1.06-1.72)*</td>
                    <td>1.14 (0.9-1.43)</td>
                    <td>1.35 (1.11-1.65)**</td>
                    <td>1.13 (0.98-1.29)</td>
                    <td>1.02 (0.73-1.41)</td>
                    <td>0.88 (0.65-1.19)</td>
                </tr>
                <tr>
                    <td>Comorbidities</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
                <tr>
                    <td>Myocardial Infarction</td>
                    <td>1.21 (0.97-1.5)</td>
                    <td>1.4 (1.06-1.84)*</td>
                    <td>1.37 (1.06-1.78)*</td>
                    <td>1.29 (1.03-1.62)*</td>
                    <td>1.21 (1.03-1.42)*</td>
                    <td>1.02 (0.7-1.48)</td>
                    <td>1.0 (0.7-1.45)</td>
                </tr>
                <tr>
                    <td>Congestive Heart Failure</td>
                    <td>1.16 (0.92-1.45)</td>
                    <td>1.48 (1.12-1.96)**</td>
                    <td>1.37 (1.04-1.79)*</td>
                    <td>1.18 (0.93-1.5)</td>
                    <td>1.11 (0.93-1.32)</td>
                    <td>1.14 (0.75-1.72)</td>
                    <td>1.14 (0.77-1.68)</td>
                </tr>
                <tr>
                    <td>Peripheral Vascular Disease</td>
                    <td>1.03 (0.83-1.27)</td>
                    <td>1.01 (0.77-1.32)</td>
                    <td>0.95 (0.73-1.23)</td>
                    <td>0.98 (0.78-1.23)</td>
                    <td>1.01 (0.86-1.18)</td>
                    <td>1.09 (0.75-1.6)</td>
                    <td>1.36 (0.95-1.95)</td>
                </tr>
                <tr>
                    <td>Cerebrovascular Disease</td>
                    <td>1.07 (0.79-1.45)</td>
                    <td>1.13 (0.77-1.64)</td>
                    <td>1.07 (0.74-1.56)</td>
                    <td>1.21 (0.89-1.64)</td>
                    <td>1.06 (0.84-1.34)</td>
                    <td>1.19 (0.7-2.02)</td>
                    <td>1.46 (0.9-2.37)</td>
                </tr>
                <tr>
                    <td>Dementia</td>
                    <td>0.74 (0.42-1.3)</td>
                    <td>1.54 (0.86-2.74)</td>
                    <td>1.34 (0.74-2.41)</td>
                    <td>0.96 (0.56-1.67)</td>
                    <td>0.96 (0.65-1.41)</td>
                    <td>1.65 (0.76-3.56)</td>
                    <td>1.45 (0.65-3.25)</td>
                </tr>
                <tr>
                    <td>Chronic Pulmonary Disease and Pneumonia</td>
                    <td>1.11 (0.89-1.39)</td>
                    <td>1.26 (0.95-1.67)</td>
                    <td>1.27 (0.97-1.67)</td>
                    <td>1.27 (1.01-1.6)*</td>
                    <td>1.18 (0.99-1.4)</td>
                    <td>1.07 (0.7-1.62)</td>
                    <td>1.59 (1.11-2.29)*</td>
                </tr>
                <tr>
                    <td>Rheumatic Disease</td>
                    <td>1.47 (1.09-1.99)*</td>
                    <td>1.48 (1.02-2.17)*</td>
                    <td>1.54 (1.07-2.22)*</td>
                    <td>1.36 (0.98-1.87)</td>
                    <td>1.4 (1.09-1.79)**</td>
                    <td>1.2 (0.64-2.24)</td>
                    <td>1.35 (0.8-2.27)</td>
                </tr>
                <tr>
                    <td>Peptic Ulcer Disease</td>
                    <td>1.02 (0.64-1.61)</td>
                    <td>1.18 (0.67-2.09)</td>
                    <td>1.11 (0.63-1.95)</td>
                    <td>1.0 (0.62-1.61)</td>
                    <td>1.49 (1.07-2.07)*</td>
                    <td>1.58 (0.77-3.23)</td>
                    <td>1.61 (0.81-3.19)</td>
                </tr>
                <tr>
                    <td>Mild Liver Disease</td>
                    <td>0.86 (0.7-1.07)</td>
                    <td>0.88 (0.67-1.16)</td>
                    <td>0.86 (0.66-1.12)</td>
                    <td>0.99 (0.8-1.24)</td>
                    <td>0.95 (0.81-1.11)</td>
                    <td>1.4 (0.98-2.01)</td>
                    <td>0.83 (0.58-1.2)</td>
                </tr>
                <tr>
                    <td>Hemiplegia or Paraplegia</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                </tr>
                <tr>
                    <td>Renal Disease</td>
                    <td>0.92 (0.72-1.18)</td>
                    <td>1.09 (0.8-1.49)</td>
                    <td>1.05 (0.78-1.41)</td>
                    <td>0.98 (0.76-1.26)</td>
                    <td>1.1 (0.92-1.32)</td>
                    <td>1.34 (0.89-2.04)</td>
                    <td>1.32 (0.87-1.99)</td>
                </tr>
                <tr>
                    <td>Moderate or Severe Liver Disease</td>
                    <td>1.45 (0.85-2.46)</td>
                    <td>1.82 (0.95-3.48)</td>
                    <td>1.79 (0.94-3.4)</td>
                    <td>1.52 (0.88-2.63)</td>
                    <td>1.5 (0.97-2.31)</td>
                    <td>0.74 (0.22-2.51)</td>
                    <td>1.54 (0.61-3.87)</td>
                </tr>
                <tr>
                    <td>Metastatic Solid Tumor</td>
                    <td>0.83 (0.42-1.63)</td>
                    <td>1.38 (0.59-3.23)</td>
                    <td>1.32 (0.58-3.02)</td>
                    <td>0.91 (0.46-1.83)</td>
                    <td>1.2 (0.75-1.9)</td>
                    <td>1.56 (0.48-5.05)</td>
                    <td>2.27 (0.75-6.87)</td>
                </tr>
                <tr>
                    <td>AIDS/HIV</td>
                    <td>0.81 (0.3-2.18)</td>
                    <td>1.15 (0.3-4.38)</td>
                    <td>2.04 (0.68-6.13)</td>
                    <td>0.79 (0.27-2.29)</td>
                    <td>1.13 (0.54-2.35)</td>
                    <td>6.45 (1.95-21.28)**</td>
                    <td>4.44 (1.29-15.3)*</td>
                </tr>
                <tr>
                    <td>Malignancy</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                    <td>0.00 (0.00-inf)</td>
                </tr>
                <tr>
                    <td>Charlson Comorbidity Index</td>
                    <td>0.99 (0.92-1.07)</td>
                    <td>0.92 (0.83-1.01)</td>
                    <td>0.92 (0.83-1.01)</td>
                    <td>0.99 (0.91-1.07)</td>
                    <td>0.97 (0.92-1.03)</td>
                    <td>0.88 (0.78-0.99)*</td>
                    <td>0.87 (0.76-0.99)*</td>
                </tr>
                <tr>
                    <td>Lifestyle Factors</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
                <tr>
                    <td>Cigarette Use</td>
                    <td>0.9 (0.76-1.06)</td>
                    <td>0.98 (0.8-1.22)</td>
                    <td>1.03 (0.84-1.27)</td>
                    <td>0.99 (0.83-1.18)</td>
                    <td>0.98 (0.86-1.11)</td>
                    <td>1.08 (0.8-1.45)</td>
                    <td>1.22 (0.92-1.61)</td>
                </tr>
                <tr>
                    <td>Alcohol Use Disorder</td>
                    <td>0.78 (0.51-1.2)</td>
                    <td>0.83 (0.48-1.42)</td>
                    <td>0.88 (0.53-1.46)</td>
                    <td>0.62 (0.38-1.0)</td>
                    <td>1.02 (0.75-1.4)</td>
                    <td>0.64 (0.27-1.5)</td>
                    <td>0.67 (0.33-1.38)</td>
                </tr>
                <tr>
                    <td>Substance Use Disorder</td>
                    <td>1.17 (0.84-1.63)</td>
                    <td>1.09 (0.72-1.65)</td>
                    <td>1.05 (0.7-1.58)</td>
                    <td>1.14 (0.8-1.61)</td>
                    <td>0.73 (0.54-0.98)*</td>
                    <td>1.56 (0.86-2.84)</td>
                    <td>1.42 (0.86-2.33)</td>
                </tr>
                <tr>
                    <td>Indicators of statistical significance:</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
                <tr>
                    <td>* &lt;0.05</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
                <tr>
                    <td>** &lt;0.01</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
                <tr>
                    <td>*** &lt;0.001</td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                </tr>
            </tbody>
        </table>

        <!-- References -->
        <h2>References</h2>
        <ol class="references">
            <li class="reference-item">Kautzky-Willer A, Leutner M, Harreiter J. Sex differences in type 2 diabetes. Diabetologia. 2023;66(6):986-1002. doi:10.1007/s00125-023-05891-x</li>
            <li class="reference-item">The All of Us Research Program Investigators. The “All of Us” Research Program. N Engl J Med. 2019;381(7):668-676. doi:10.1056/NEJMsr1809937</li>
            <li class="reference-item">Qian Gu P, Feng Zeng P, Bimal V. Patel P, Louis C. Tripoli MD. Part D Coverage Gap and Adherence to Diabetes Medications. 2010;16. Accessed September 26, 2024. <a href="https://www.ajmc.com/view/ajmc_10dec_gu_911to918" target="_blank">https://www.ajmc.com/view/ajmc_10dec_gu_911to918</a></li>
            <li class="reference-item">Ferrannini G, De Bacquer D, Vynckier P, et al. Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys. Cardiovasc Diabetol. 2021;20(1):38. doi:10.1186/s12933-021-01233-6</li>
            <li class="reference-item">Bhuyan SS, Shiyanbola O, Deka P, et al. The Role of Gender in Cost-Related Medication Nonadherence Among Patients with Diabetes. J Am Board Fam Med. 2018;31(5):743-751. doi:10.3122/jabfm.2018.05.180039</li>
            <li class="reference-item">Raparelli V, Proietti M, Romiti GF, et al. The Sex-Specific Detrimental Effect of Diabetes and Gender-Related Factors on Pre-admission Medication Adherence Among Patients Hospitalized for Ischemic Heart Disease: Insights From EVA Study. Front Endocrinol. 2019;10. doi:10.3389/fendo.2019.00107</li>
            <li class="reference-item">Garfield R, Orgera K, Damico A. The Coverage Gap: Uninsured Poor Adults in States that Do Not Expand Medicaid.</li>
            <li class="reference-item">Parker ED, Lin J, Mahoney T, et al. Economic Costs of Diabetes in the U.S. in 2022. Diabetes Care. 2024;47(1):26-43. doi:10.2337/dci23-0085</li>
        </ol>
    </div>

    <footer>
        &copy; Sex Based Disparities in Cost Related Medication Nonadherence in Older Adult Patients with Type 2 Diabetes from the All of Us Database
    </footer>

</body>
</html>
